In assessing surrogate clinical trial end points: drug safety is a requisite.
University of Cincinnati Cancer Institute, Cincinnati, OH thomas.herzog@uc.edu.
Thomas J
TJ
Herzog
The University of Texas MD Anderson Cancer Center, Houston, TX.
Robert L
RL
Coleman
University of Arizona Cancer Center, Phoenix, AZ.
Bradley J
BJ
Monk
Hopkins Kimmel Cancer Center, Baltimore, MD.
Deborah K
DK
Armstrong
University of Alabama at Birmingham, Birmingham, AL.
Ronald D
RD
Alvarez
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D040262:Receptors, Vascular Endothelial Growth Factor